• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Investigating and Resolving Cardiotoxicity Induced by COVID-19 Treatments using Human Pluripotent Stem Cell-Derived Cardiomyocytes and Engineered Heart Tissues
Adv Sci (Weinh). 2022 Sep 2:e2203388. doi: 10.1002/advs.202203388. Online ahead of print.ABSTRACTCoronavirus disease 2019 continues to spread worldwide. Given the urgent need for effective treatments, many clinical trials are ongoing through repurposing approved drugs. However, clinical data regarding the cardiotoxicity of these drugs are limited. Human pluripotent stem cell-derived cardiomyocytes (hCMs) represent a powerful tool for assessing drug-induced cardiotoxicity. Here, by using hCMs, it is demonstrated that four antiviral drugs, namely, apilimod, remdesivir, ritonavir, and lopinavir, exhibit cardiotoxicity in term...
Source: Adv Data - September 2, 2022 Category: Epidemiology Authors: He Xu Ge Liu Jixing Gong Ying Zhang Shanshan Gu Zhongjun Wan Pengcheng Yang Yage Nie Yinghan Wang Zhan-Peng Huang Guanzheng Luo Zhongyan Chen Donghui Zhang Nan Cao Source Type: research

Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes
CONCLUSION: Transcriptional profiling in hiPSC-CMs treated with COVID-19 drugs identified unfavorable changes with lopinavir/ritonavir and lopinavir/ritonavir/INF-β in key cardiac gene programs that may negatively affect heart function.PMID:35686037 | PMC:PMC9170897 | DOI:10.3389/fcvm.2022.844441
Source: Methods of Information in Medicine - June 10, 2022 Category: Information Technology Authors: Tobias Jakobi Julia Gro ß Lukas Cyganek Shirin Doroudgar Source Type: research

Therapeutic strategies for COVID-19 patients: An update
Infect Disord Drug Targets. 2022 Mar 22. doi: 10.2174/1871526522666220322145729. Online ahead of print.ABSTRACTThe novel coronavirus SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread causing a global pandemic that infected more than 444 million people, resulting in severe social and economic ramifications, and claimed more than 6,010,000 lives by March 5, 2022. The pandemic attracted global attention with consequential multiple economic, social, and clinical studies. Among causes of poor clinical outcome of the disease are therapeutic challenges, leading to spirals of studies in search for better...
Source: Infectious Disorders Drug Targets - March 23, 2022 Category: Infectious Diseases Authors: Muhammad Ibrahim Getso Soudabeh Etemadi Vahid Raissi Moein Mohseni Maedeh Sadat Mohseni Farid Raeisi Omid Raiesi Source Type: research

A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review
The emergence of highly virulent CoVs (SARS-CoV-2), the etiologic agent of novel ongoing “COVID-19” pandemics has been marked as an alarming case of pneumonia posing a large global healthcare crisis of unprecedented magnitude. Currently, the COVID-19 outbreak has fueled an international demand in the biomedical field for the mitigation of the fast-spreading illness, all through the urgent deployment of safe, effective, and rational therapeutic strategies along with epidemiological control. Confronted with such contagious respiratory distress, the global population has taken significant steps towards a more robust strat...
Source: Frontiers in Pharmacology - February 26, 2021 Category: Drugs & Pharmacology Source Type: research

Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena
Coronavirus disease 2019 (COVID-19), an acute onset pneumonia caused by a novel Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the Wuhan City of China in December 2019 and evolved into a global pandemic. To date, there are no proven drugs or vaccines against this virus. Hence, the situation demands an urgent need to explore all potential therapeutic strategies that can be made available to prevent the disease progression and improve patient outcomes. In absence of clinically proven treatment guidelines, several repurposed drugs and investigational agents are currently being evalua...
Source: Frontiers in Pharmacology - September 16, 2020 Category: Drugs & Pharmacology Source Type: research